ESMO Gynaecological Cancers Congress 2024
Towards a brighter future for gynaecological cancers
Improvements in the understanding of molecular mechanisms, together with a greater focus on prevention, are key elements to countering gynaecological malignancies
Disappointing early results for niraparib plus dostarlimab in the treatment of relapsed endometrial or ovarian carcinosarcomas
The phase II part of the ROCSAN trial failed to meet its primary endpoint but there may be potential for benefit based on efficacy and safety data with the combination
Platinum-resistant ovarian cancer: mirvetuximab soravtansine benefits are maintained in patients who require dose modifications
New survival data from the MIRASOL trial support the use of this antibody-drug conjugate as a preferred standard of care for patients with high folate receptor alpha tumour expression
Durvalumab plus olaparib show sustained PFS improvements in newly diagnosed non-BRCA-mutated ovarian cancer
While updated results from the DUO-O trial appear promising, they are not conclusive due to the study design
PD-1 inhibition plus chemoradiotherapy is effective across ethnicities in locally advanced cervical cancer
However, studies highlight cost as an obstacle to widespread accessibility in some countries
The promises of antibody-drug conjugates for ovarian cancer
A multitude of new agents under development could finally offer meaningful treatment options to a patient population with high unmet need